MBL77 NO FURTHER A MYSTERY

mutations, in whom rituximab seems to obtain tiny added price.59 Other genomic subgroups, including patients with BIRC3translocations or amplifications along with the genomic alterations already current in the first CLL, but deficiency the popular mutations noticed in Major DLBCL indicating that they may correspond to another biological classificat